WebDisclosure WebDisclosure
Basculer en Français
10966 Companies
240147 Keywords
168916 Articles
129236 Press releases
Headlines Articles Press releases SkywardRX Remove
  1. Home
  2. Companies
  3. SkywardRX
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 02/21/2024 at 15:00, 2 years 6 months ago

    SkywardRx et Victoria's Voice Foundation Unissent Leurs Forces Contre la Crise des Opiacés

    SkywardRx Victoria's Voice Foundation Prévention Des Drogues Naloxone Epidémie D'opioïdes
  • BRIEF

    published on 02/21/2024 at 15:00, 2 years 6 months ago

    SkywardRx and Victoria's Voice Foundation Join Forces Against the Opioid Crisis

    Opioid Epidemic SkywardRx Victoria's Voice Foundation Naloxone Drug Prevention
  • PRESS RELEASE

    published on 02/21/2024 at 15:00, 2 years 6 months ago

    SkywardRx Forges Alliance With Victoria's Voice Foundation to Propel Naloxone Awareness Across Extensive Distribution Channels

    SkywardRx partners with Victoria's Voice Foundation to enhance drug education and naloxone access, aiming to combat the opioid crisis through innovative initiatives in 2024
    SkywardRx Victoria's Voice Foundation Drug Education Naloxone Access Opioid Crisis
    Logo of SkywardRX
Accesswire
  • Published on 09/12/2026 at 02:35, 22 hours 35 minutes ago

    Gamma Resources Announces Extension of Private Placement Closing Date

  • Published on 09/11/2026 at 23:00, 1 day 2 hours ago

    Rio Grande Resources Engages Machai Capital for Investor Outreach

  • Published on 09/11/2026 at 22:05, 1 day 3 hours ago

    Usha Resources Announces Leadership Transition

  • Published on 09/11/2026 at 21:25, 1 day 3 hours ago

    Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects

  • Published on 09/11/2026 at 17:00, 1 day 8 hours ago

    Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE
EQS Group
  • Published on 09/12/2026 at 17:50, 7 hours 19 minutes ago

    New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South

  • Published on 09/12/2026 at 07:30, 17 hours 39 minutes ago

    NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia

  • Published on 09/11/2026 at 22:15, 1 day 2 hours ago

    Amrize Appoints Mario Gross as President of Building Envelope

  • Published on 09/11/2026 at 22:10, 1 day 2 hours ago

    Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference

  • Published on 09/11/2026 at 19:44, 1 day 5 hours ago

    DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

View all EQS
Les Echos
  • Published on 09/11/2026 at 07:00, 1 day 18 hours ago

    Transparantiekennisgeving van Baltisse Groep

  • Published on 09/11/2026 at 07:00, 1 day 18 hours ago

    Transparency notification by Baltisse Group

  • Published on 09/11/2026 at 07:00, 1 day 18 hours ago

    BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY

  • Published on 09/11/2026 at 07:00, 1 day 18 hours ago

    BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ

  • Published on 09/10/2026 at 19:30, 2 days 5 hours ago

    Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy